Infliximab
- Generic Name
- Infliximab
- Brand Names
- Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 170277-31-3
- Unique Ingredient Identifier
- B72HH48FLU
- Background
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...
- Indication
用于治疗：
⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；
⑵克罗恩病及瘘管性克罗恩病；
⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。
⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版
】。
⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。
- Associated Conditions
- Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
- Associated Therapies
- -
Infliximab Accelerated Induction in Moderate to Severe Pediatric UC
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Schneider Children's Medical Center, Israel
- Target Recruit Count
- 10
- Registration Number
- NCT03209232
- Locations
- 🇮🇱
Schenider Children's Medical Center, Petaẖ Tiqwa, Israel
Infliximab Biosimilar in Takayasu's Arteritis
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Ospedale San Raffaele
- Target Recruit Count
- 30
- Registration Number
- NCT03192878
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele, Milano, MI, Italy
Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Istituto Clinico Humanitas
- Target Recruit Count
- 100
- Registration Number
- NCT03151525
- Locations
- 🇮🇹
IBD Center, Rozzano, MI, Italy
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT03112603
- Locations
- 🇵🇷
Incyte Investigative Site, Ponce, Puerto Rico
🇬🇧Novartis Investigative Site, Manchester, United Kingdom
🇷🇴Novartis Investigational Site, Bucharest, Romania
Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-09-19
- Target Recruit Count
- 208
- Registration Number
- NCT03100253
- Locations
- 🇮🇹
Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹Azienda Consorziale Ospedaliera Policlinico, Bari, Italy
🇮🇹Azienda Socio Sanitaria Territoriale - Papa Giovanni XXIII, Bergamo, Italy
Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)
- Conditions
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Hospices Civils de Lyon
- Registration Number
- NCT03088293
KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 105
- Registration Number
- NCT03065244
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Emory University
- Target Recruit Count
- 42
- Registration Number
- NCT03006393
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Inflammation-Induced CNS Glutamate Changes in Depression
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 22
- Registration Number
- NCT03004443
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Anti-TNF Therapy for Refractory Colitis in Hospitalized Children
- Conditions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 38
- Registration Number
- NCT02799615
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Connecticut Children's Hospital Medical Center, Hartford, Connecticut, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.